

Appendix 2: Annual direct per capita costs related to severity or treatment in individuals with type 2 diabetes

		Ratio ‡	95%-CI
Sex	women	reference	
	men	0.98	[0.77 - 1.23]
Age	[years]	1.01	[1.00 - 1.02]
Weight	[BMI]	1.03	[1.00 - 1.06]
Education	primary	reference	
	secondary	1.39	[0.97 - 1.99]
	tertiary	0.94	[0.63 - 1.41]
Treatment	no medication	reference	
	with OAD only	1.12	[0.79 - 1.59]
	with OAD and insulin	1.69	[1.08 - 2.66]
	with insulin only	2.16	[1.30 - 3.58]
Diabetes duration	0-2 years	reference	
	3-10 years	0.84	[0.57 - 1.24]
	11-19 years	1.12	[0.73 - 1.74]
	≥ 20 years	1.70	[0.93 - 3.12]
Glycemic control	HbA1c <6.5%	reference	
	HbA1c 6.5%-7.5%	0.78	[0.59 - 1.03]
	HbA1c 7.5%-9%	0.76	[0.55 - 1.05]
	HbA1c >9%	1.02	[0.60 - 1.74]
CVD complications	no CVD complications	reference	
	CVD complications	1.45	[1.14 - 1.86]

GEE models with a gamma distribution and a log link. Models based on 9,160 observations from 6,803 subjects. 1€ was assigned to observations with zero costs. Models are accounted for the repeated measurement structure.

Missing values on BMI, treatment, diabetes duration, glycemic control and complications (in total n=126) were imputed using a regression based imputation method

‡ exponentiated estimate

OAD: oral antidiabetic drugs

** Significant at the level of 1%.

* Significant at the level of 5%.